Targeting MRPs holds promise for improving cancer treatment outcomes. Inhibitors of MRPs can potentially reverse drug resistance by blocking the efflux of chemotherapy drugs, thereby increasing their intracellular concentrations and enhancing their cytotoxic effects. Several MRP inhibitors are under investigation, including small molecules and monoclonal antibodies aimed at specific MRPs.
